RLAY241220P7500
- 2.00
- 0.000.00%
Relay Therapeutics Newsroom
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $20
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Relay Therapeutics Price Target Raised to $20.00/Share From $19.00 by HC Wainwright & Co.
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $27
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $17
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $21
Buy Rating on Relay Therapeutics: Promising Developments and Strong Financial Position
TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Relay Therapeutics (RLAY)
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $19
HC Wainwright & Co. Reiterates Buy on Relay Therapeutics, Maintains $19 Price Target
Relay Therapeutics Analyst Ratings
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $17
巴克莱银行维持Relay Therapeutics(RLAY.US)买入评级，维持目标价17美元
Relay Therapeutics (RLAY) Receives a Buy From Barclays
Relay Therapeutics: A Buy Rating on Robust RLY-2608 Performance and Strategic Trial Design
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $28
Relay Therapeutics Price Target Maintained With a $28.00/Share by Stifel
Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.